Phoreus Biotech

Executive Summary

Phoreus Biotech is a preclinical-stage biotechnology company developing next-generation Peptide Nanoparticles (PNPs) for targeted drug delivery. Founded in 2018 and headquartered in San Diego, the company addresses key limitations of traditional carriers by enabling the delivery of diverse therapeutic cargoes—including nucleic acids, proteins, and small molecules—through less invasive routes. Its proprietary PNP platform aims to improve efficacy, reduce off-target effects, and expand the therapeutic index of various drugs. Despite being in early development, Phoreus's technology has potential applications across multiple disease areas, including oncology, genetic disorders, and infectious diseases. The company is privately held and has not disclosed funding rounds or valuation, indicating an early-stage profile with limited public information. Its success hinges on advancing preclinical studies, securing partnerships, and raising capital to move toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-Enabling Studies40% success
• TBDSeries A Funding Announcement50% success
• TBDResearch Partnership or Licensing Deal35% success